Showing results (441-450 of 2,755) with videos related to
Sort By:
Pageof 276
Pharmacogenomics|August 7, 2008
Molecular basis for statin-induced muscle toxicity: implications and possibilitiesCatherine Buettner, Stewart H LeckerPharmacogenomics|August 7, 2008
Is pharmacogenomics our future? Metformin, ovulation and polymorphism of the STK11 gene in polycystic ovary syndromeNaila Goldenberg, Charles J GlueckPharmacogenomics|September 11, 2008
Pharmacogenomic importance of pravastatinBas Peters, Anke-Hilse Maitland-van der ZeePharmacogenomics|September 11, 2008
Variations in the UDP-glucuronosyltransferase 1A1 gene for the development of unconjugated hyperbilirubinemia in TaiwaneseYang-Yang Huang, May-Jen Huang, Sieng-Sien Yang, et al.Pharmacogenomics|September 11, 2008
Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapyMarta Spreafico, Corrado Lodigiani, Y van Leeuwen, et al.Pharmacogenomics|September 11, 2008
Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogeneticsBk Thelma, Vibhuti Srivastava, Arun Kumar TiwariPharmacogenomics|September 11, 2008
Ethnic differences in warfarin maintenance dose requirement and its relationship with geneticsHedi Schelleman, Nita A Limdi, Stephen E KimmelPharmacogenomics|August 12, 2009
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosingStuart A Scott, Malgorzata Jaremko, Steven A Lubitz, et al.Pharmacogenomics|August 12, 2009
Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancerJean-Louis Formento, Marie-Christine Etienne-Grimaldi, Mireille Francoual, et al.Pharmacogenomics|August 12, 2009
Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonanceDonna K Arnett, Steven A ClaasPageof 276